Country: Ireland
Language: English
Source: HPRA (Health Products Regulatory Authority)
TAMOXIFEN CITRATE
Generics (UK) Limited
L02BA01
TAMOXIFEN CITRATE
20 Milligram
Tablets
Product subject to prescription which may be renewed (B)
tamoxifen
Marketed
1986-03-14
Colours Non-Print Colours Date: Time: Equate CMYK with Dimensions Main Font Body Text Size Min Text Size used Page Count No. of colours Pharma Code SAP No. Vendor Job No. Trackwise Proof No. Glams Proof No. Client Market Keyline/Drawing No. Barcode Info Description Component Type Affiliate Item Code Superceded Affiliate Item Code TrackWise PR No. MA No. Packing Site/Printer Supplier Code Sign-offs v1/May 2015 1/4 1 Times New Roman 9 pt 09 FEB 2016 11:31 180 x 210 mm Tamoxifen Citrate 10 mg,20 mg 30 Leaflet 779779 503742 779779 PA0405/1/1 PA0405/1/2 Delpharm 5034659 202 N/A 273637 1 Ireland N/A N/A N/A Black Glue Area 9 pt PACKAGE LEAFLET: INFORMATION FOR THE PATIENT TAMOXIFEN 10 MG TABLETS TAMOXIFEN 20 MG TABLETS (as tamoxifen citrate) READ ALL OF THIS LEAFLET CAREFULLY BEFORE YOU START TAKING THIS MEDICINE BECAUSE IT CONTAINS IMPORTANT INFORMATION FOR YOU. • Keep this leaflet. You may need to read it again. • If you have any further questions, ask your doctor or pharmacist. • This medicine has been prescribed for you only. Do not pass it on to others. It may harm them, even if their signs of illness are the same as yours • If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. See section 4. WHAT IS IN THIS LEAFLET: 1. What Tamoxifen is and what it is used for 2. What you need to know before you take Tamoxifen 3. How to take Tamoxifen 4. Possible side effects 5. How to store Tamoxifen 6. Contents of the pack and other information The name of your medicine is Tamoxifen 10 mg or 20 mg Tablets (referred to as Tamoxifen in this leaflet). 1. WHAT TAMOXIFEN IS AND WHAT IT IS USED FOR Your medicine comes as a tablet containing the active ingredient tamoxifen which is an ANTI-OESTROGEN. It is used in the treatment of breast cancer. Some tumours are dependent on female sex hormones, oestrogens, in order to grow. As an anti-oestrogen, tamoxifen can prevent naturally occurring oestrogens attaching to tumour cells, which are dependent on th Read the complete document
SUMMARY OF PRODUCT CHARACTERISTICS 1 NAME OF THE MEDICINAL PRODUCT Tamoxifen 20 mg Tablets 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Each tablet contains tamoxifen citrate equivalent to 20 mg of tamoxifen. For the full list of excipients, see section 6.1. 3 PHARMACEUTICAL FORM Tablet Tamoxifen 20mg Tablet: White, round, biconvex tablet debossed with 'TN' above the score and '20' below the score on one side of the tablet and 'G' on the other side. 4 CLINICAL PARTICULARS 4.1 THERAPEUTIC INDICATIONS Tamoxifen is indicated in the treatment of breast cancer_._ 4.2 POSOLOGY AND METHOD OF ADMINISTRATION Posology BREAST CANCER: Adults (including the elderly): The dosage range is 20 to 40 mg daily, given either in divided doses twice daily or as a single dose once daily. In early disease, it is currently recommended that treatment is given for not less than 5 years. The optimal duration of tamoxifen therapy remains to be determined. _Paediatric population:_ The use of tamoxifen is not recommended in children, as safety and efficacy have not been established (see sections 5.1 and 5.2). Method of administration For administration by the oral route. 4.3 CONTRAINDICATIONS Tamoxifen should not be used in the following: pregnancy. There have been a small number of reports of spontaneous abortions, birth defects and foetal deaths after women have taken tamoxifen, although no causal relationship has been established (see also section 4.6). hypersensitivity to the active substance, or to any of the excipients listed in section 6.1. H E A L T H P R O D U C T S R E G U L A T O R Y A U T H O R I T Y ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ _ Read the complete document